Q4FY25 Quarterly Activities Report/Appendix 4C
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
23 July 2025
Q4FY25 Quarterly Activities Report
SYDNEY Australia 23 July 2025 – Tetratherix Limited (ASX: TTX) is pleased to release its
Appendix 4C and quarterly activities report for the period ended 30 June 2025 (Q4 FY25).
Key highlights for the quarter:
Tetratherix signs exclusive strategic licencing agreement with Bio Optix Inc.
•
•
•
•
The strategic licence agreement focused on development and commercialisation
of an ophthalmic viscoelastic device (OVD), built on the Tetratherix polymer
platform.
BioOptix, based in New York, USA, is an ophthalmic company founded and led by
experienced physicians and is a portfolio company of AdAstral Labs, bringing
deep clinical knowledge and commercial experience to the partnership.
The global OVD market, with an estimated total addressable value of
approximately USD700 million, is currently dominated by a select few major
medical technology players.
The Tetratherix-BioOptix collaboration aims to disrupt this status quo by
launching custom-engineered OVD material specifically designed for use in the
eye.
“We tailored our platform technology to meet the clinical requirements for OVD
applications, such as optical transparency and thermo-reversibility. This can provide
better experience and clinical outcomes for up to 20 million patients globally.” – Dr
Ali Fathi, CTO of Tetratherix.
•
•
•
•
Tetratherix will become a minority shareholder in BioOptix under the Strategic
Licence Agreement.
The Agreement includes key milestones that are expected to deliver licencing
income to Tetratherix, expected from FY26.
BioOptix will fund all US FDA regulatory approval activities in relation to the
products developed through the partnership.
Once commercialised, Tetratherix will manufacture the products developed
under the partnership at its Australian based facilities, under its ISO13485
certified quality management system. Minimum purchase quantities of 1 million
units for the initial 5 years post-commercialisation are agreed.
1
Tetratherix completes Tutelix FDA pre-submission
•
•
Tutelix Pty Ltd (Tutelix: Tetratherix 50% joint venture partner) completed a presubmission meeting with the US FDA to progress the regulatory pathway for the Tutelix
product under the company’s tissue spacing franchise. FDA pre-submission
indicated the product classification as a Class II, the product code, and the predicate
for the 510(k) clearance of Tutelix.
Key details, in relation to clinical trial synopsis for the clearance of the product, were
also confirmed; these include the number of patients and follow up period, primary
and secondary end points. Based on the current trajectory, US FDA 510(k) clearance
of the Tutelix prostate spacer remains on track for FY28.
Tetratherix lists on ASX
•
•
•
•
On 30 June 2025 Tetratherix successfully listed on the ASX raising $25 million of
primary capital (with no secondary issuance) through the issue of 8,680,000 new
shares at $2.88 per share, at an implied market capitalisation of $145 million.
The Company’s IPO represents a pivotal inflection point enabling it to accelerate the
growth of the first products built on the Company’s proprietary TetramatrixTM platform.
The Tetratherix board and management acknowledges the support of the ASX in
enabling Tetratherix to become an Australian listed entity poised for global expansion.
Tetratherix board and management would also like to acknowledge and thank its longterm shareholders, partners and new investors who supported the IPO.
Company Financial commentary
•
•
•
Strong cash on hand position $A29.3million as 30 June 2025, with zero debt
financing.
$3.9m cash outflows for May and June 2025, reflected in Appendix 1 use of funds
table, driven by IPO costs and investment in R&D programs.
Tetratherix is in a strong position to continue its focus on investment in
Research and Development and expansion of its advanced manufacturing
capabilities with its closing cash balance in line with prospectus assumptions.
2
•
In accordance with ASX Listing Rule 4.7C.3, Tetratherix advises that an amount of
$115k was paid during the quarter to Tetratherix Directors in salary and
director’s fees.
“This was a pivotal quarter for Tetratherix, following our listing on the ASX where we
successfully raised $25 million. We are delighted with the continued delivery on our key
strategic milestones. These include securing our BioOptix license agreement and
completion of our FDA pre submission for Tutelix. We commence Q1FY26 with a strong
cash on hand position of $29.3m which will enable us to successfully invest in our R&D
and production expansion as we embark on this next stage of growth.” – Will Knox, CEO
of Tetratherix
Q1 and Q2 FY26 Key Business Priorities
•
•
•
•
•
Tutelix first in human (FIH) clinical study to be initiated in Gold Coast, QLD. This
provides a critical inflection point in assessment of the product’s performance
and safety under the tissue spacing franchise. Additionally, this will enable Tutelix
Pty Ltd to design and implement its US/AU pivotal clinical trial for FDA-510(k)
clearance.
Tegenix and TegeEOS regulatory clearance path is to progress as planned by
completion of FDA pre-clinical studies, with expected timelines on track for
product clearances in H2 FY26. These US FDA-510(k) clearances will enable the
company’s strategy to continue its commercialisation activities under its bone
regeneration franchise with its corporate partners.
TetraDerm clinical trial to progress with patients to be recruited in Cohort 2,
involving surgical incisions in face/neck. Achieving the primary end points for this
stage of the trial will enable the progression of the trial for the Company’s longerterm strategy, including FDA pre-submission and confirming potential corporate
partnerships for the tissue healing franchise.
Quality surveillance audit is to be completed with the objective for Tetratherix to
maintain its ISO13485 certification, governing its quality management system,
production and design and development activities.
New facility lease negotiations are expected to be completed with an agreement
that will enable manufacturing expansion in FY27 and beyond.
Authorised for release by CEO and CFO.
For further information contact:
Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au
https://tetratherix.com/
3
About Tetratherix
Tetratherix is an Australian medical technology company pioneering advanced
biomaterial solutions to transform how complex diseases are treated. Our proprietary
polymer platform enables the targeted delivery of cells, drugs and biologics, unlocking
new potential across oncology, regenerative medicine and more. Tetratherix combines
deep scientific innovation with real-world clinical impact – underpinned by a novel
business model designed for global scalability and embedded collaboration with
partners and healthcare systems around the world.
Overview of Tetratherix’s current product portfolio
TetramatrixTM is the Company’s current core platform technology. This platform
technology is safe and clinically modular and therefore used to co-develop multiple
products in partnership with leading medical companies. The overarching aim to use
TetramatrixTM platform technology in developing multiple products is to treat patients
faster, cheaper and safer. The current portfolio of products under development with
TetramatrixTM spans several large near-term commercial opportunities that are grouped
into three franchises:
•
Bone regeneration: relates to the utility of TetramatrixTM platform’s technology to
develop products to support bone repair in dental and orthopaedic applications.
•
Tissue spacing: relates to the utility of TetramatrixTM platform technology to develop
products to generate space between two tissues or organs either to support surgical
access for ophthalmic applications or to reduce side effects to surrounding tissue
and organs during cancer treatment; and
•
Tissue healing: relates to the utility of TetramatrixTM platform technology to develop
product for use during any open surgical intervention to reduce scar formation at
the incision site.
Table 1. Three distinct markets that address unmet needs in five separate medical indications.
4
See more at www.tetratherix.com
Forward-looking statements
This announcement may contain forward-looking statements which may be identified by
words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”,
and other similar words that involves risks and uncertainties. Such statements are not
guarantees of future performance and involve known and unknown risks, uncertainties,
assumptions and other important factors, many of which are beyond the control of
Tetratherix or its Directors and management and could cause Tetratherix’s actual results
and circumstances to differ materially from the results and circumstances expressed or
anticipated in these statements. The Directors cannot and do not give any assurances
that the results, performance or achievements expressed or implied by the forwardlooking statements contained in this announcement will actually occur and investors are
cautioned not to place undue reliance on these forward-looking statements.
5
Appendix 1
In accordance with ASX Listing Rule 4.7C Tetratherix provides the following use of funds
information:
Prospectus
A$m
USE OF FUNDS
Research and Development Bone Regeneration
Research and Development Tissue Healing
Research and Development Tissue Spacing
Research and Development Precision Medicine
Manufacturing expansion
Listed company costs and directors fees
Costs of the offer ($0.4m expensed YTD Apr 25)
Working capital
Total
REF
1-4
1
2
3
4
5
6
7
8
9
2.4
5.3
2.3
1.3
10.2
2.5
3.4
5.8
33.2
May-Jun 25
Actual
as %
Accumulated prospectus
0.1
0.5
0.0
0.0
0.1
3.0
0.2
3.9
Ref
2%
9%
0%
0%
0%
4%
89%
4%
12%
Comment
R&D costs include specific projects, directly attributable staff, research
and laboratory costs, trademarks, patent filing and upkeep. Specific
breakdown by project as follows
Bone Regeneration: activity focused on preparation for FDA clearance
Tissue Healing: ongoing clinical trial and pipeline development
Tissue Spacing: No significant expenditure in May and June 25
Precision Medicine: No significant expenditure in May and June 25
Manufacturing expansion: To commence in FY26
Listed company costs: Reflects board remuneration, audit fees, share
registry, directors’ and officers’ insurance and company secretary services
IPO costs: YTD April costs included in Opening cash balance for UOF.
Includes costs of the offer. Final invoices to be paid Q1 2026; on track to
prospectus.
Working capital: Includes finance costs, employee and contractor costs
computer costs and general operating expenses
UOF at $33.2m includes $8.2m existing cash on hand as at 30/4 as per
prospectus plus $25 million capital raise funding.
$3.9m Total outflows May- June 2025
$29.3m Closing cash balance 30 June 2025
6
1
2
3
4
5
6
7
8
9
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Tetratherix Limited
ABN
Quarter ended (“current quarter”)
72 607 771 077
30 June 2025
Current quarter
$A’000
Consolidated statement of cash flows
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date (12
months) $A’000
0
0
(277)
(938)
(a)
research and development
(b)
product manufacturing and operating costs
0
0
(c)
advertising and marketing
0
0
(d)
leased assets
(13)
(53)
(e)
staff costs
(582)
(1,762)
(f)
administration and corporate costs
(288)
(917)
1.3
Dividends received (see note 3)
0
0
1.4
Interest received
85
90
1.5
Interest and other costs of finance paid
0
(2)
1.6
Income taxes paid
0
0
1.7
Government grants and tax incentives
0
830
1.8
Other (provide details if material)
0
0
1.9
Net cash from / (used in) operating activities
(1,075)
(2,752)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a)
entities
0
0
(b)
businesses
0
0
(c)
property, plant and equipment
(146)
(567)
(d)
investments
0
0
(e)
(f)
intellectual property
other non-current assets
0
0
0
0
7
Current quarter
$A’000
Consolidated statement of cash flows
2.2
Year to date (12
months) $A’000
Proceeds from disposal of:
(a)
entities
0
0
(b)
businesses
0
0
(c)
property, plant and equipment
0
0
(d)
investments
0
0
(e)
intellectual property
0
0
(f)
other non-current assets
0
0
2.3
Cash flows from loans to other entities
0
0
2.4
Dividends received (see note 3)
0
0
2.5
Other (provide details if material)
0
0
2.6
Net cash from / (used in) investing activities
(146)
(567)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
24,998
24,998
3.2
Proceeds from issue of convertible debt
securities
0
11,015
3.3
Proceeds from exercise of options
0
0
3.4
Transaction costs related to issues of equity
securities or convertible debt securities
(3,277)
(3,468)
3.5
Proceeds from borrowings
0
0
3.6
Repayment of borrowings
0
(20)
3.7
Transaction costs related to loans and
borrowings
0
0
3.8
Dividends paid
0
0
3.9
Other (provide details if material)
0
0
3.10
Net cash from / (used in) financing activities
21,721
32,525
4.
Net increase / (decrease) in cash and cash
equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
8,836
127
4.2
Net cash from / (used in) operating activities
(item 1.9 above)
(1,075)
(2,752)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(146)
(567)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
21,721
32,525
4.5
Effect of movement in exchange rates on cash
held
4.6
Cash and cash equivalents at end of period
8
3
29,336
29,336
5.
Reconciliation of cash and cash equivalents
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5.2
Current quarter
$A’000
Previous quarter
$A’000
29,336
8,836
Call deposits
0
0
5.3
Bank overdrafts
0
0
5.4
Other (provide details)
0
0
5.5
Cash and cash equivalents at end of quarter
(should equal item 4.6 above)
29,336
8,836
6.
Payments to related parties of the entity and their associates
6.1
Aggregate amount of payments to related parties and their associates
included in item 1
88
6.2
Aggregate amount of payments to related parties and their associates
included in item 2
0
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments.
6.1 Note: Payments to related payments include directors’ fees and lease payments to Pacific Interactive Pty
Ltd who is an entity controlled by a Shareholder of the Company.
7.
Financing facilities
Note: the term “facility’ includes all forms of
financing arrangements available to the entity.
Total facility amount
at quarter end
$A’000
Amount drawn at
quarter end
$A’000
Add notes as necessary for an understanding of
the sources of finance available to the entity.
7.1
Loan facilities
0
0
7.2
Credit standby arrangements
0
0
7.3
Other (please specify)
0
0
7.4
Total financing facilities
0
0
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest rate,
maturity date and whether it is secured or unsecured. If any additional financing facilities have been
entered into or are proposed to be entered into after quarter end, include a note providing details of
those facilities as well.
Not applicable
9
0
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(1,075)
8.2
Cash and cash equivalents at quarter end (item 4.6)
29,336
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by item 8.1)
0
28,621
26 (note 1)*
Note 1*: Q4 FY25 cash from operating activities relates to a pre-listed business. Per TTX’s prospectus the Use of Funds is forecast
to fund operations and capital expenditure from May 2025-June 2027.
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the
estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating cash
flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further cash to
fund its operations and, if so, what are those steps and how likely does it believe that they will
be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
10
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
23rd July 2025
Authorised by: By the Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has
been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing
activities, depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the
board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert
here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the
market by a disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out
as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles
and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the
financial records of the entity have been properly maintained, that this report complies with the appropriate accounting
standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the
basis of a sound system of risk management and internal control which is operating effectively.
11
Share your feedback
Discover